Servier Moves Into Muscular Dystrophy, Paying $1.5B for Assets From Edgewise TherapeuticsNews DeskJune 1, 20260 Servier is expanding its scope in neurology to include neuromuscular disorders by acquiring a clinical-stage Edgewise Therapeutics drug that offers…